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Recent work has shown that a DBF4 analog in yeast may be a target of nitrogen-containing
bisphosphonates. DBF4 is an essential protein kinase required for DNA replication from primary eu-
karyotes to humans and appears to play a critical role in the S-phase checkpoint. It is also required for cell
migration and cell surface adhesion. The effects of Pamidronate, risedronate, or zoledronate on cell
viability and DBF4 expression were measured via MTT assays and western blotting. In addition, FACS cell
cycle analyses and invasion assays were conducted in cells in the presence of nitrogen-containing
bisphosphonates to identify any correlations between DBF4 expression and S-phase arrest or anti-
invasive effects of the bisphosphonates. Zoledronate transiently down-regulated DBF4 expression in
all three cell lines in the ﬁrst 24 h of the experiment, but after 72 h, DBF4 expression returned to the
control levels in all treated cells. Following treatment of the tumor cells with the bisphosphonates, the
number of cells in S-phase was increased. Pamidronate and zoledronate showed anti-invasive effects in
BT20 cells. The anti-invasive effects of pamidronate, risedronate and zoledronate appeared after 48 h of
exposure. In MDA-MB231 cells a reduction of invasiveness was only observed after 72 h of the
pamidronate exposure. We ﬁnally concluded that the anti-invasive and cell cycle arrest-inducing effects
of nitrogen-containing bisphosphonates are not DBF4 mediated, and other mediators are therefore
needed to explain the observed complex behaviors.
 2013 Elsevier Masson SAS. All rights reserved.1. Introduction
Bisphosphonates are a series of synthetic compounds that are
widely used in the treatment of bone metabolic diseases associated
with high bone resorption, including destructive arthropathy,
ﬁbrous dysplasia, heterotopic ossiﬁcation, osteogenesis imperfecta,
and Paget’s disease [1]. Bisphosphonates are chemically and
enzymatically stable and resemble pyrophosphate analogs char-
acterized by a PeCeP bond [2]. The germinal carbon in this moiety
is covalently bonded to two different lateral chains that are usually
referred to as the R1 and R2 groups. R1 and R2 confer a pronounced
binding afﬁnity for hydroxyapatite and antiresorptive properties in
bone, respectively. Based on their molecular structure and mech-
anism of action, two distinct types of bisphosphonates have beennjan University of Medical
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such as clodronate and etidronate, are metabolized to form
potentially cytotoxic analogs of ATP that accumulate in cells and
deactivate osteoclasts, leading to cell death [1]. In contrast,
nitrogen-containing bisphosphonates (NBPs), such as alendronate,
ibandronate, pamidronate, risedronate, and zoledronate, inhibit
intracellular farnesyl diphosphate synthase (FPPS) in the mevalo-
nate pathway, which results in decreased levels of farnesyl
diphosphate and geranylgeranyl diphosphate and inhibition of the
prenylation of GTP-binding proteins (such as Ras, Rho, and Rac),
which is considered to represent the main mechanism of osteoclast
activity inhibition and apoptosis promotion [3,4].
Although these bioactive agents are only FDA approved for the
treatment of bone metabolic diseases, they have recently gained
attention due to their strong apoptosis induction effect in human
myeloma cells [5], immunomodulation and stimulation of cytotoxic
T-cells targeting tumor cells [4], inhibition of tumor angiogenesis
[3], inhibition of the adhesion of invasive cancer cells to bone
matrices [6], inhibition of cell invasion and proliferation, and
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in uncovering the mechanisms underlying these anticancerous and
immunomodulatory properties. Induction of caspase activity
(especially caspase-3 or caspase-7), progressive decreases in the
bcl2/bax ratio, and inhibition of the mevalonate pathway are
important apoptotic mechanisms associated with the effects of
bisphosphonates on tumor cells [4,5]. Interestingly, NBPs down-
regulate vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) expression and show potential anti-
angiogenetic effects [7]. However, little is known about the mo-
lecular mechanisms underlying the anti-invasive and cell cycle
arrest-inducing effects of NBPs, and it appears that more complex
pathways may be involved. A large-scale experiment examining
different yeast mutants in the presence of sub-lethal doses of some
NBPs revealed the YDR052C protein (yeasts analog of human DBF4)
as a secondary cellular target for these agents [8]. DBF4 is a regu-
latory subunit of the Cdc7 serine/threonine-speciﬁc protein kinase,
which is a checkpoint effector enzyme for the initiation of DNA
replication and entry into S-phase of the cell cycle [9]. Cdc45 and
MCM proteins that bind to replication origins and activate the
replication initiation complex are phosphorylated by Cdc7-DBF4.
Cdc7 is consistently expressed during the cell cycle, while DBF4
decreases during G1 phase and increases during S and G2 phases.
Therefore, up-regulation of DBF4 promotes S-phase [10]. It has also
been demonstrated that DBF4 phosphorylates integrin and that
depletion of DBF4 kinase reduces cell attachment to collagen-I-
coated surfaces in some cells. DBF4 also plays a critical role in cell
adhesion and migration, possibly through regulation of actin
cytoskeleton arrangement [11]. Although yeast experiments have
shown that the anti-invasive and S-phase arrest-inducing effects of
NBPsmay bemediated via the YDR052C protein, further studies are
needed to conﬁrm these mechanisms in human cells. Considering
all of these ﬁndings, the present study focuses on analysis of the
relationship between NBP treatment and DBF4 expression levels in
three different human cell lines and the potential consequences of
the biological effects of NBPs on the cell cycle and migration
behavior.
2. Materials and methods
2.1. Chemicals and media
RPMI-1640medium, trypsin, fetal bovine serum (FBS), penicillin
and streptomycin were purchased from Gibco (Grand Island, NY,
USA). Pamidronate, risedronate, zoledronate, monoclonal anti-
human b-actin (mouse IgG1), monoclonal anti-human DBF4 (goat
IgG) antibodies, and an HRP-conjugated secondary antibody (goat
anti-mouse IgG) were obtained from Santa Cruz biotechnology
(California, USA). Complete Mini Protease Inhibitor Cocktail Tab-
lets came from Roche Applied Science (Mannheim, Germany). All
other chemicals and solvents were of analytical grade and were
purchased from Merck (Darmstadt, Germany).
2.2. Cell lines and cell proliferation assay
The BT20, MDA-MB231, and T47D human epithelial breast
cancer cell lines were purchased from the Pasteur Cell Bank, Iran.
The cells were cultured in RPMI-1640 medium supplemented with
2 mM L-glutamine, 10% (v/v) heat-inactivated FBS, 100 IU/ml
penicillin, and 100 mg/ml streptomycin at a constant temperature of
37 C in a humidiﬁed CO2 incubator. Proliferation characteristics
were determined according to methods used in previous studies by
our group. Brieﬂy, 1000 cells were seeded into each well of 96-well
plates in 200 ml of growth medium. The culture medium was
refreshed every 2 days. Cell growth was assessed during a 7-dayincubation period using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). After 3 h of incubation with
MTT (5 mg/ml), the production of formazan crystals was measured
using the TECAN microplate reader at 650 nm. All experiments
were run three independent times in triplicate, and the results
were expressed as the mean values  SE [12,13].
2.3. Cell cytotoxicity assay
The cells were cultured at a density of 1000 cells per well in 96-
well plates and incubated at 37 C for 24 h. A stock solution of
10 mM pamidronate, risedronate, and zoledronate in 1 phosphate
buffered saline (PBS) was prepared and stored in aliquots at20 C.
The stock was freshly diluted with culture medium before use and
added to microplates at deﬁned concentrations from 0 to 100 mM.
Cell viability was evaluated after a 5-day incubation of the treated
cells using MTT assays. The IC50 was determined as the drug con-
centration that reduced the surviving fraction of cells in each well
by 50% compared to the control. All experiments were performed
three independent times in triplicate, and the results were
expressed as the mean values  SE [12,14].
2.4. Protein extraction and quantiﬁcation
The cancer cell lines were cultured in 6-well plates at a density
of 6  105 cells/well and incubated at 37 C for 24 h. The cells were
then treated with 100 mMpamidronate, risedronate, or zoledronate
for 24, 48, or 72 h, followed by being washed twice with cold PBS.
Next, 300 ml of RIPA lysis buffer (5 mM EDTA, 150 mM NaCl, 1% v/v
Triton X-100, 0.1% w/v SDS, 50 mM TriseHCl pH 8.0 supplemented
with a Complete Mini Protease Inhibitor Cocktail Tablet) was
added to approximately 106 exponentially growing cells, followed
by incubation on ice for 30 min. Cellular lysates were scraped and
collected from culture plates, after which they were centrifuged at
14000 g for 10 min, and the supernatant (containing total intra-
cellular proteins) was isolated. The supernatant protein content
was measured with the BCA Protein Assay Kit (Thermo Scientiﬁc,
Rockford, IL, USA), according the manufacturer’s protocol, at
562 nm using serial dilutions of human serum albumin as the
standard. Unless otherwise speciﬁed, all protein extraction pro-
cedures were carried out at 4 C. Finally, the protein samples were
stored at 80 C until further use [15].
2.5. SDS-PAGE and western blotting analysis
The equivalent of 50 mg of each protein sample was mixed with
6 loading buffer (300 mM DTT, 20% v/v glycerol, 4% w/v SDS,
0.3% w/v bromophenol blue, and 120 mM TriseHCl pH 6.8), heated
for 2 min at 95 C, and then centrifuged at 12000 g for 1 min at
4 C. The samples were next loaded into the wells of a 12% SDS-
PAGE gel and electrophoresed in running buffer (190 mM glycine,
0.1% w/v SDS, 25 mM TriseHCl pH 8.0) for 1.5 h (90 V). The sepa-
rated proteins were electro-blotted onto a 0.45 mm nitrocellulose
membrane (Portran, Whatman, Germany), stained with Ponceau-
S, and washed twice with TBS-T (TBS containing 0.5% v/v tween-
20). The nitrocellulose membranes were pre-blocked with TBS-T
containing 5% skimmed milk powder for 1 h at room temperature
to reduce nonspeciﬁc primary antibody binding. Following three
washes with TBSeT, the blots were incubated with a diluted mouse
monoclonal antibody directed against either human DBF4 (1:600)
or human b-actin (1:600) in TBS-T supplemented with 5% skimmed
milk overnight at 4 C. Then, the membranes were treated with the
corresponding HRP-conjugated goat anti-mouse IgG (1:5000) in
the same supplemented buffer for 1 h at room temperature. The
protein-antibody complexes were visualized using a luminol-based
M. Mansouri et al. / Biochimie 99 (2014) 71e76 73detection system (Thermo Scientiﬁc, Rockford, IL, USA) according to
the manufacturer’s protocol. Antibody binding was subsequently
visualized via exposure of the membrane to blue light-sensitive X-
ray ﬁlm (Kodak, Tokyo, Japan). Immunoﬂuorescence reactions were
carried out using at least three independent protein extracts [16].
2.6. Cell cycle analysis
The breast cancer cell lines were seeded into 6-well plates at a
density of 6  105 cells/well for 24 h. Then, the cells were treated
with 100 mMpamidronate, risedronate, or zoledronate for 24, 48, or
72 h. Approximately 2.5  105 cells were harvested, washed twice
using ice-cold PBS, and resuspended in 200 ml of cold PBS. For rapid
cell ﬁxation and dispersion, the cell suspensions were added drop-
wise to 1 ml of cold 70% ethanol and incubated on ice for 45 min.
After centrifugation, the cells were resuspended in 1ml of PI master
mix (PBS containing 100 mg/ml RNase A and 40 mg/ml propidium
iodide) and incubated in the dark at 37 C for 30 min. The various
cell cycle phases were monitored using a FACSCalibur ﬂow cy-
tometer (BD Biosciences, San Jose, CA). Cells were excited at 488 nm
with an argon laser, and the emission from ten thousand cells was
recorded using a 580 nm band-pass ﬁlter (FL2-H). For discrimina-
tion of G1 doublet cells from G2/M single cells, a dot blot graph of
the FL2-W versus FL2-A data was also plotted. The obtained cell
cycle proﬁles were analyzed using CellQuest version 3.2 and
WinMDI version 2.8 softwares. All experiments were performed
three independent times in duplicate [17].
2.7. Invasion assay
The breast cancer cell lines were seeded into 6-well plates at a
density of 6  105 cells/well for 24 h, after which they were treated
with 100 mMpamidronate, risedronate, or zoledronate for 24, 48, or
72 h. Approximately 2  105 cells were then harvested in serum-
free medium and overlaid in the upper chambers of insertion
plates (8 mm pore size; SPL, South Korea) that were uniformly
coated with 1 mg/ml BD BioCoat Matrigelmatrix (BD Biosciences,
California, USA). The cells were subjected to a 24 h serum starvation
period prior to seeding. The lower chambers were ﬁlled with 10%
(v/v) FBS-supplemented RPMI-1640 as a chemoattractant. After
24 h of incubation at 37 C in the humidiﬁed CO2 incubator, the
non-invading cells located in the upper portion of chamber were
removed with cotton swabs. The numbers of adherent cells on the
bottom of each insert were determined by MTT assays using a
standard curve prepared from serial dilutions of the corresponding
cell line [18].
2.8. Statistical analysis
All experiments were carried out in triplicate at least three in-
dependent times, and the means  standard errors were reported.
Quantitative data from the experiments were analyzed using Stu-
dent’s t-test. P-values less than 0.05 were considered to be statis-
tically signiﬁcant.
3. Results
3.1. Cell proliferation and cell cytotoxicity assays
The cells grew as amonolayer attached to the bottomof the ﬂask
and had the appearance of small round clumps. The growth char-
acteristics of the cell lines were determined via MTT dye reduction
assays over seven days (Supplementary Fig. 1S). To investigate the
effects of NBPs on cell survival, the breast cancer cell lines BT20,
MDA-MB231, and T47D were treated with increasing doses of eachNBP. A doseeresponse curve was ﬁtted to our data, and the IC50
values were calculated after 5 days of exposure through MTT cell
viability assays (Fig. 1). The most cytotoxic compound in the MDA-
MB-231 and T47D cells was zoledronate (P < 0.01, P < 0.001), with
IC50 values of approximately 7 and 22 mM being recorded, respec-
tively. However, pamidronate was more potent (IC50 7 mM) in the
BT20 cell line compared with the other NBPs (P< 0.01, Table 1). The
obtained data showed that the cytotoxic effects of the NBPs are cell
speciﬁc.
3.2. Effects of NBP on DBF4 expression
After the extraction of total proteins from the cells, the levels of
DBF4 protein expression were determined via western blotting
analysis. DBF4 and b-actin appeared in their full-length forms as
bands at approximately 37 and 49 kDa, respectively. Although DBF4
expression was not altered in the presence of pamidronate and
risedronate in any of the cell lines, zoledronate transiently down-
regulated DBF4 expression in all three cell lines in the ﬁrst 24 h
of the experiment. After 72 h, DBF4 expression returned to the
control levels in all cells. In fact, there were no differences between
the DBF4 levels in any of the NBP-treated cells and control samples
after 72 h of treatment (Fig. 2).
3.3. Effects of NBPs on the cell cycle
Cell cycle progression was analyzed via ﬂow cytometry after
propidium iodide staining. The distribution of cells in different
phases conﬁrmed previous reports that have shown that NBPs can
cause cell cycle arrest in S-phase. Following treatment of the tumor
cells with 100 mM pamidronate, risedronate, or zoledronate, an
increase in the number of cells in S-phase accompanied by a
reduction in the proportion in G0/G1 or G2/M phase was noted
(Fig. 3 and Supplementary Table 1S). The percentage of cells in S-
phase increased progressively in a time-dependent manner with
continuing exposure to the three drugs. The increase in the pro-
portion of cells in S-phase was more evident in the presence of
zoledronate, particularly after the longest (72 h) period of exposure
(additional data are given in Supplementary Table 1S). The results
indicated that the NBPs down-modulated tumor cell proliferation
via inducing cell cycle arrest at S-phase.
3.4. NBP treatment and cell invasion
The invasive behavior of cells cultured in the presence and
absence of NBPs at different times was examined via trans-well
migration assays. Here, 2  105 starved cells treated with 100 mM
pamidronate, risedronate, or zoledronate for 24, 48, or 72 h were
seeded into trans-well chambers with or without Matrigel. The
invasion percentage for each treatment was calculated by dividing
the number of migrating cells in the Matrigel-coated chambers by
the number of migrating cells in uncoated chambers
(Supplementary Table 2S). Division of the invasion percentage for
each treatment by the value for the corresponding control yields
the invasion index. Pamidronate and zoledronate showed anti-
invasive effects in BT20 cells at all experimental time points
(P < 0.001). In contrast, risedronate had no effects on the invasive
behavior of the BT20 cells at any time point. The anti-invasive ef-
fects of the NBPs on the T47D cells appeared after 48 h of treatment
(P < 0.001). In the MDA-MB231 cells, a reduction of invasiveness
was only observed after 72 h of pamidronate exposure (P < 0.001;
Fig. 4 and Supplementary Table 2S). The results indicated that the
anti-invasive effects of the NBPs were time dependent and cell type
speciﬁc.
Fig. 1. Effects of mitoxantrone, pamidronate, risedronate, or zoledronate on the survival of BT20 (A), MDA-MB231 (B), and T47D (C) cells. The cells were cultured for 5 days with
increasing doses of NBPs from 0 to 100 mM. Cell survival was measured by MTT assay. The values represent the means of three independent experiments performed in triplicate
(Mean  SE). Mit: mitoxantrone, Pam: pamidronate, Ris: risedronate, and Zol: zoledronate.
Table 1









T47D 69.4  3.26 70.8  4.13 22.2  2.93 0.03  0.004
MDA- MB231 9.5  0.73 15.5  1.02 7.3  0.61
3.0  0.21
BT20 7.6  0.43 9.0  0.56 13.9  0.98 0.169  0.005
Data represent the mean  standard error of three individual experiments.
a Drug concentration (mM) required for 50% inhibition of cell growth after 5 days
of drug exposure.
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Since the discovery of bisphosphonates in 1968 [19], these
molecules have been clinically approved to reduce bone turnover,Fig. 2. Western blotting of DBF4 and b-actin. BT20, MDA-MB231, and T47D cells were treate
cell lysates were prepared at each individual time point and subjected to western blotting to
DBF4 and b-actin individually after stripping. b-Actin was used as an internal control. Pamincrease bone mass, confer signiﬁcant fracture protection and
eliminate bonemetastasis due to common cancers, such as prostate
and breast cancers. NBPs have also recently been the subject of
many anticancer studies. These promising studies have provided
valuable information about the pharmacological effects of NBPs.
Despite the tremendous amount of work already conducted on this
topic, several fundamental issues remain to be addressed, including
the mechanisms underlying the promotion of apoptosis and cell
cycle arrest, induction of T-cell cytotoxicity against tumor cells,
inhibition of angiogenesis, inhibition of cell proliferation, reduction
of cellular adhesion, and reduction of invasion by NBPs [4,20]. The
established inhibition of protein prenylation in the mevalonate
pathway does not allow interpretation of many of the new phar-
macological effects of NBPs. Therefore, recent studies have aimed to
identify new targets for these effects. For example, it has been re-
ported that a DBF4 analog in a mutant yeast collection may be ad with 100 mM pamidronate, risedronate, or zoledronate for 24, 48, or 72 h, and whole-
identify the levels of DBF4 expression. The blots were treated with antibodies against
: pamidronate, Ris: risedronate, and Zol: zoledronate.
Fig. 3. Cell cycle phase alterations following NBPs treatment of human breast cancer cell lines. BT20, MDA-MB231, and T47D cells were treated with 100 mM pamidronate,
risedronate, or zoledronate for 24, 48, or 72 h. The cells were then harvested, ﬁxed and stained with propidium iodide for ﬂow cytometric cell cycle analysis. Con: Control, Pam:
pamidronate, Ris: risedronate, and Zol: zoledronate.
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sents an essential checkpoint at the G1/S transition for replication
initiation and DNA synthesis via phosphorylation of the MCM
helicase complex. The MCM helicase is assembled in replicationFig. 4. The invasion index of the BT20 (A), MDA-MB231 (B), and T47D (C) cells in the pre
zoledronate for 24, 48, or 72 h. Invasion assays were performed using trans-well chambers c
absence or presence of Matrigel. The invasion index was quantiﬁed by division of the percen
invasion data represent mean values from three separate experiments (Mean  SE). Con: Cforks during late G1-phase and triggers origin unwinding and ﬁring
of DNA synthesis. These results suggest that the execution of MCM
function is dependent on DBF4 [21]. On the other hand, a DBF4-
mediated phosphorylation cascade involving integrin andsence of the NBPs. The cells were treated with 100 mM pamidronate, risedronate, or
oated with the basement membrane Matrigel. The migrating cells were counted in the
tage of invasion for each treatment by the corresponding control values. The presented
ontrol, Pam: pamidronate, Ris: risedronate, and Zol: zoledronate.
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migration. Bone, which is comprised of more than 90% collagen-I, is
the most frequent site of metastasis for several common cancers.
DBF4 depletion reduces integrin and collagen phosphorylation and
cell attachment to collagen-I-coated surfaces and inhibits cell
migration and invasion. Therefore, blocking this key molecule in-
hibits tumor cell migration and adhesion to the new sites, which
could ultimately reduce metastasis [11]. Striking evidence has
shown that the DBF4 protein is scarce or undetectable in normal
tissues and cell lines but is up-regulated in approximatelyw50% of
human tumor cell lines, and some tumor cells also exhibit extra
copies of the DBF4 gene. Therefore, increased DBF4 abundance may
be a sign of malignancy in humans [22]. To gain a better under-
standing of whether the cell cycle arrest or invasion inhibition
brought about by NBPs may occur via DBF4-mediated kinase ac-
tivity, we have conducted extensive molecular analyses in several
human cancer cell lines.
The present study showed that NBPs reduce overall cell growth
in the BT20, MDA-MB231, and T47D breast cancer cell lines. These
toxic effects are drug and cell speciﬁc (Table 1 and Fig. 1). Zoledr-
onate was the most toxic agent in each of the three cell lines, and
most of the cells tolerated risedronate better than the other NBPs. It
also appears that MDA-MB231 cells aremore sensitive to the effects
of the NBPs than the other cell lines. As seen in the western blot
analyses, zoledronate was the only NBP that caused a transient
down-regulation of DBF4. However, all three NBPs caused cells to
accumulate in S-phase of the cell cycle, with a corresponding
decrease in the number of cells in other phases being observed
during the experiment. The elevation of the percentage of cells in S-
phase is not DBF4-mediated, at least based on the following two
reasons. First, DBF4 down-regulation is expected to arrest cells in
G1-phase; however, the transient down-regulation observed in
zoledronate-treated cells was associated with accumulation of the
cells in S-phase. Second, risedronate and pamidronate did not alter
DBF4 expression, but the cell count in S-phase increased each day
for all treatments during the three days of the experiment. The
same simple reasons also refute the idea that the anti-invasive
function of NBPs is DBF4 mediated. Interestingly, while DBF4
depletion is expected to reduce cell attachment and cell invasion, in
the present study, though cell invasion was reduced after three
days of NBP treatment, the DBF4 contents in the treated cells were
almost equal to those in the controls at this time point. In general,
the results obtained via western blotting and from cell cycle and
invasion analyses in the investigated cancer cell lines provided
insight into the DBF4-independent invasion inhibition and cell
cycle arrest stimulated by NBP treatment, contributing to our un-
derstanding of the complexity of this regulatory mechanism [23].
Interestingly, although DBF4 expression was transiently down-
regulated on the ﬁrst day of zoledronate treatment in the three
cell lines, we found no clear evidence that DBF4 down-regulation
was associated with the effects of bisphosphonates treatment
regarding cell cycle arrest or cancer cell invasion and metastasis.
Therefore, novel signalingmediators should reveal potential targets
for pharmacological interventions using NBPs to induce cell cycle
arrest or prevent metastasis.
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